Detalhe da pesquisa
1.
Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
Osteoporos Int
; 32(1): 173-184, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200257
2.
Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.
Osteoporos Int
; 32(9): 1879-1888, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33606045
3.
Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting.
Osteoporos Int
; 30(6): 1287-1295, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30809724
4.
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Osteoporos Int
; 26(2): 699-712, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25432773
5.
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Osteoporos Int
; 26(9): 2365-74, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25929192
6.
Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Osteoporos Int
; 25(1): 367-76, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23716037
7.
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.
Osteoporos Int
; 23(1): 233-45, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21369791
8.
Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Osteoporos Int
; 26(11): 2721, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26359183
9.
Erratum to: Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Osteoporos Int
; 26(11): 2719-20, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26377424
10.
Bisphosphonate effects and the bone remodeling transient.
J Bone Miner Res
; 12(8): 1143-51, 1997 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-9258743
11.
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
J Bone Miner Res
; 17(11): 1988-96, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12412806
12.
Stimulation by calcitonin gene-related peptide of atrial natriuretic peptide secretion in vitro and its mechanism of action.
Endocrinology
; 124(5): 2473-9, 1989 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-2468474
13.
Evidence supporting a two-receptor model for insulin binding by cultured embryonic heart cells.
Endocrinology
; 107(1): 195-207, 1980 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-6991248
14.
Relationship of insulin binding to amino acid transport by cultured 14-day embryonic chick heart cells.
Endocrinology
; 104(4): 1059-68, 1979 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-436747
15.
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group.
J Clin Endocrinol Metab
; 85(9): 3109-15, 2000 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-10999794
16.
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.
Bone
; 27(5): 687-94, 2000 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-11062357
17.
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
Bone
; 18(2): 141-50, 1996 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-8833208
18.
Role of nutrition and exercise in osteoporosis.
Am J Med
; 82(1B): 73-9, 1987 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-3544836
19.
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
Am J Med
; 101(5): 488-501, 1996 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-8948272
20.
Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.
Am J Med
; 103(4): 291-7, 1997 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-9382121